Health Technology Assessments (HTAs) systematically evaluate the properties, impacts, and effects of treatments or medical devices to guide decisions on their adoption, use, or reimbursement. They address medical, social, economic, and ethical aspects to promote efficient and effective use of health resources.(https://health.ec.europa.eu/health-technology-assessment/overview_en)

Over the past decade patient groups have been engaging in this process, aiding interested parties in their decision-making. PatientView’s latest June -August 2024 ‘Patients in Action’ survey investigated the scale and nature of the patient group involvement in HTA. The responses reflect the patient groups perspectives. responses from 548 patient groups, of which 252 provided qualitative feedback.

The analyses tackles the following questions:

  • Do HTA authorities consider patient organisations essential to the healthcare system?
  • Do patient groups represent patients’ interests to drug-regulatory authorities?
  • Do Health Technology Assessment (HTA) authorities provide support to patient groups?
  • How are patient groups involved in HTA?

Click play to watch the PowerPoint below: